Role of Circulating MicroRNAs in Pathogenesis of Aneurysms of

Status Recruiting

Clinical Trial Summary

The objective of this study is to establish whether patients with aortic aneurysm, compared to general population, have higher levels of selected miRNAs and whether there is significant association between the level of miRNA in circulating blood and the size of the aortic aneurysm or the risk of its rupture.

Clinical Trial Description

Aneurysm of the abdominal and thoracic aorta represents a major cause of cardiovascular morbidity and mortality. The course of this condition can stay asymptomatic for long, and its first manifestation can be acute rupture of the aneurysm sac with life-threatening bleeding. Detection of patients at risk and their early treatment significantly reduce the percentage of this potentially lethal complications.

Aortic diseases are most often degenerative processes with a varying involvement of genetic predisposition. In literature, a substantial number of genes were proved to affect the metabolism of the vessel wall and to determine production of structural proteins, which were associated with the vascular pathologies. Pathophysiologic mechanisms of lesions of the aortic wall have not been completely understood. Among other, they include endothelial dysfunction, chronic inflammation of the vessel wall, apoptosis of smooth muscle cells and degradation of the extracellular matrix, resulting in the loss of integrity of layers of the vessel wall and decrease in its strength, which leads to dilation, rupture or dissection. Apart from mutations in genes coding the structural proteins of the vessel wall, many other potential biomarkers were proposed for early diagnosis of aortic aneurysm. These include microRNA (miRNA), one-fibre chains of non-coding ribonucleic acid which are several nucleotides long and are involved in the gene expression through the mechanism of inhibition of mRNA translation or increase in its degradation. Recently, association of levels of these miRNAs to presence and growth of aortic aneurysms has been described. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03090763
Study type	Observational
Source	Charles University, Czech Republic
Contact	Jean Claude Lubanda, MD., Ph.D.
Phone	00420224962692
Email	Jean-Claude.Lubanda@vfn.cz
Status	Recruiting
Phase	N/A
Start date	November 1, 2016
Completion date	June 1, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04149600` - Identification of Genetic Causes of Calcific Aortic Valve Disease
Enrolling by invitation	`NCT04035356` - HAART Annuloplasty Device Valve Repair Registry
Recruiting	`NCT02729064` - Intraoperative Nasal Insulin Effect on Plasma and CSF Insulin Concentration and Blood Glucose	Phase 1
Completed	`NCT02467062` - Implementation of Non-size Markers Derived From 4D Flow MRI of Patients With Aortic Disease.	N/A
Completed	`NCT02283307` - Dual Energy CT Urography With Reduced Iodinated Contrast	N/A
Completed	`NCT01678261` - X-chromosome Inactivation, Epigenetics and the Transcriptome	N/A
Terminated	`NCT01055275` - Cook Iliac Branch Graft Post-market Registry	N/A
Completed	`NCT00615888` - Fast Track Management in Elective Open Infrarenal Aortic Aneurysm Repair	N/A
Completed	`NCT03510793` - Microcirculation and Anesthesia in Vascular Surgery
Completed	`NCT03207568` - RE-GENERATION: The Safety and Performance of the Relay Pro and Relay NBS Pro Stent-graft Devices in the European Union (EU)	N/A
Recruiting	`NCT05073991` - Incidence of Mortality and Complications After Lung Surgery, Open Thoracic Aortic Repair, TEVAR, EVAR.
Not yet recruiting	`NCT01918969` - Reference Values of Circulating Endothelial Progenitor Cells	N/A
Not yet recruiting	`NCT01918982` - Circulating Endothelial Progenitor Cells and Aortic Aneurysm	N/A
Completed	`NCT02000544` - Clinical Evaluation of a Modular Extracorporeal Circulation Circuit	N/A
Completed	`NCT01256372` - An Trial of Two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Surgery	Phase 2
Recruiting	`NCT00661518` - PET/CT Imaging of Aneurysm Wall Inflammation	N/A
Completed	`NCT00094575` - Standard Open Surgery Versus Endovascular Repair of Abdominal Aortic Aneurysm (AAA)	Phase 4
Recruiting	`NCT04471909` - NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness	N/A
Recruiting	`NCT05603520` - Phenotyping Heterogeneity and Regionality of the Aorta
Completed	`NCT03727542` - Influence of Short AV Delay Permanent Pacing on Matrix Metalloproteinase Levels	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Role of Circulating MicroRNAs in Pathogenesis of Aneurysms of the Abdominal and Thoracic Aorta - Study "Micro AAA"

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms